Key result
Trabectedin blocks FUS-DDIT3 binding to restore adipocyte differentiation in myxoid liposarcoma xenografts.
Why the study?
The role of the FUS-DDIT3 chimeric protein in the mechanism of action of trabectedin against myxoid liposarcoma is not entirely understood.
Trabectedin exerts its efficacy against myxoid liposarcoma by detaching the FUS-DDIT3 chimera from DNA, restoring adipocyte differentiation.
Answers are grounded in this paper and cite their sources.
Trabectedin restores adipogenesis via FUS-DDIT3 detachment in sensitive PDX models; leaves open resistance mechanisms and clinical translation.
BACKGROUND: The marine drug trabectedin has shown unusual effectiveness in the treatment of myxoid liposarcoma (MLPS), a liposarcoma characterized by the expression of the FUS-DDIT3 chimera. Trabectedin elicits a significant transcriptional response in MLPS resulting in cellular depletion and reactivation of adipogenesis. However, the role of the chimeric protein in the mechanism of action of the drug is not entirely understood. METHODS: FUS-DDIT3-specific binding sites were assessed through Chromatin Immunoprecipitation Sequencing (ChIP-Seq). Trabectedin-induced effects were studied on pre-established patient-derived xenograft models of MLPS, one sensitive to (ML017) and one resistant against (ML017ET) trabectedin at different time points (24 and 72 h, 15 days). Data were integrated with RNA-Seq from the same models. RESULTS: Through ChIP-Seq, here we demonstrate that trabectedin inhibits the binding of FUS-DDIT3 to its target genes, restoring adipocyte differentiation in a patient-derived xenograft model of MLPS sensitive to trabectedin. In addition, complementary RNA-Seq data on the same model demonstrates a two-phase effect of trabectedin, characterized by an initial FUS-DDIT3-independent cytotoxicity, followed by a transcriptionally active pro-differentiation phase due to the long-lasting detachment of the chimera from the DNA. Interestingly, in a trabectedin-resistant MLPS model, the effect of trabectedin on FUS-DDIT3 rapidly decreased over time, and prolonged treatment was no longer able to induce any transcription or post-transcriptional modifications. CONCLUSIONS: These findings explain the unusual mechanism underlying trabectedin's effectiveness against MLPS by pinpointing the chimera's role in inducing the differentiation block responsible for MLPS pathogenesis. Additionally, the findings hint at a potential mechanism of resistance acquired in vivo.
No takes yet. Share an insight, caveat, or question.
Craparotta et al. (2024) studied Myxoid liposarcoma (preclinical PDX models). Trabectedin vs. Saline was evaluated on FUS-DDIT3 genomic distribution and transcriptional modulation (assessed via ChIP-Seq and RNA-Seq). Trabectedin inhibits the binding of the FUS-DDIT3 chimeric protein to its target genes, restoring adipocyte differentiation in a sensitive patient-derived xenograft model of myxoid liposarcoma.
Synapse has enriched 10 related papers. Consider them for comparative context: